Conventionally approved drugs are mostly AChE inhibitors, increasing the amount of ACh in the synapses and decelerating the advancement of AD (Reddy et al., 2017; Li et al., 2018; Patel et al., 2020). This evidence concerns the gene ACHE and Alzheimer disease.